|
|
||||||||
1The Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina; and 2Charité-University Medicine Berlin, Berlin, Germany
Submitted 1 November 2006 ; accepted in final form 12 February 2007
Angiotensin-converting enzyme-2 (ACE2) converts angiotensin II (ANG II) to angiotensin-(17) [ANG-(17)], and this enzyme may serve as a key regulatory juncture in various tissues. Although the heart expresses ACE2, the extent that the enzyme participates in the cardiac processing of ANG II and ANG-(17) is equivocal. Therefore, we utilized the Langendorff preparation to characterize the ACE2 pathway in isolated hearts from male normotensive Sprague-Dawley [Tg()] and hypertensive [mRen2]27 [Tg(+)] rats. During a 60-min recirculation period with 10 nM ANG II, the presence of ANG-(17) was assessed in the cardiac effluent. ANG-(17) generation from ANG II was similar in both the normal and hypertensive hearts [Tg(): 510 ± 55 pM, n = 20 vs. Tg(+): 497 ± 63 pM, n = 14] with peak levels occurring at 30 min after administration of the peptide. ACE2 inhibition (MLN-4760, 1 µM) significantly reduced ANG-(17) production by 83% (57 ± 19 pM, P < 0.01, n = 7) in the Tg(+) rats, whereas the inhibitor had no significant effect in the Tg() rats (285 ± 53 pM, P > 0.05, n = 10). ACE2 activity was found in the effluent of perfused Tg() and Tg(+) hearts, and it was highly associated with ACE2 protein expression (r = 0.78). This study is the first demonstration for a direct role of ACE2 in the metabolism of cardiac ANG II in the hypertrophic heart of hypertensive rats. We conclude that predominant expression of cardiac ACE2 activity in the Tg(+) may be a compensatory response to the extensive cardiac remodeling in this strain.
angiotensin II; hypertension; isolated heart
This article has been cited by other articles:
![]() |
C. Schindler ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 233 - 248. [Abstract] [PDF] |
||||
![]() |
P. J. Garabelli, J. G. Modrall, J. M. Penninger, C. M. Ferrario, and M. C. Chappell Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart Exp Physiol, May 1, 2008; 93(5): 613 - 621. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. I. Diz, M. A. Garcia-Espinosa, S. Gegick, E. N. Tommasi, C. M. Ferrario, E. Ann Tallant, M. C. Chappell, and P. E. Gallagher Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats Exp Physiol, May 1, 2008; 93(5): 694 - 700. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Trask, J. A. Jessup, M. C. Chappell, and C. M. Ferrario Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2242 - H2247. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |